NCT00033215|CompletedPhase 1FDA Drug
Loading search results
Sponsor study identifier
interventional
32
1 country
4
Study Start
November 2001
Actual (reported)Primary Completion
February 13, 2003
Actual (reported)Study Completion
March 12, 2003
Actual (reported)To determine the maximum tolerated dose and safety profile of S-3304 in patients with biopsy accessible cancer who have failed previous therapy or to whom no standard therapies are available. To determine the pharmacokinetic profile of S-3304 in this patient population
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 12, 2003
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2001
Actual (reported)April 9, 2002
Actual (reported)April 10, 2002
Actual (reported)February 13, 2003
Actual (reported)March 12, 2003
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
University of Colorado Hospital
Denver, Colorado, 80262, United States
H. Lee Moffitt Concer Center and Research Institute
Tampa, Florida, 33612, United States
Roswell Park Cancer Center
Buffalo, New York, 14263, United States
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, Yamada-Sawada T, Kambayashi Y, Tanaka K, Javle MM, Mekhail T, O'bryant CL, Creaven PJ. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2091-9. doi: 10.1158/1078-0432.CCR-06-1586.
32 participants (actual enrollment reported by the registry).
First Submitted
April 9, 2002
First Posted
April 10, 2002
Study Start
Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors
Contact the study team to confirm eligibility.
November 2001
Primary Completion
February 13, 2003
Actual (reported)Study Completion
March 12, 2003
Actual (reported)Last Updated
April 26, 2018
Record last verified: 2018-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: